The Promise and Limitations of TNF-α Inhibition for Uveitis

References

• Cunningham ET Jr, Zierhut M. TNF inhibitors for uveitis: balancing efficacy and safety. Ocul Immunol Inflamm 2010;18:421–423
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr. Treatment of chronic noninfectious uveitis in children–the trend toward tumor necrosis factor-alpha inhibition. J AAPOS 2013;17:451–453
   PubMedGoogle Scholar
• Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibition for ophthalmic indications: current status and outlook. BioDrugs 2013;27:347–357
   PubMed Web of Science ®Google Scholar
• Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm 2014; 22: 96–101
   Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014; 22: 90–95
   Google Scholar
• Tsang AD, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm 2014; In press. Ocul Immunol Inflamm 2014; 22: 155–157
   Google Scholar
• Martel JN, Sterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 2012;20:18–26
   PubMed Web of Science ®Google Scholar
• Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-α inhibitors. J Rheumatol. 2013;40:1394–1403
   PubMed Web of Science ®Google Scholar
• Artornsombudh P, Pistilli M, Foster CS, et al. Factors Predictive of Remission of New-Onset Anterior Uveitis. Ophthalmology 2013; Dec 14. pii: S0161-6420(13)00886-5. doi: 10.1016/j.ophtha.2013.09.041. [Epub ahead of print]
   Google Scholar
• Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum. 2010;62:2796–2805
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr, Goldstein DA, Zierhut M. Uveitis treatment trials – A cross trial perspectives. Ocul Immunol Inflamm 2012;20:63–67
   PubMed Web of Science ®Google Scholar
• Zierhut M, Abu El-Asrar AM, Bodaghi B, Tugal-Tutkun I. Therapy of ocular behçet disease. Ocul Immunol Inflamm. 2014;22:64–76
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol 2013;31:320–321
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Salom D, Díaz-Llopis M, et al. Golimumab for uveitis. Ophthalmology 2011;118:1892. e3–4
   Google Scholar
• Mesquida M, Victoria Hernández M, Llorenç V, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm 2012;19:160–162
   Google Scholar
• William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect 2012;2:231–233
   PubMedGoogle Scholar
• Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Experiment Ophthalmol. 2013 Sep 11. doi: 10.1111/ceo.12207. [Epub ahead of print]
   Google Scholar
• Muselier A, Bielefeld P, Bidot S, et al. Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocul Immunol Inflamm. 2011;19:382–383
   PubMed Web of Science ®Google Scholar
• Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39:1294–1295
   PubMed Web of Science ®Google Scholar
• Knoll A, Lutz T, Grulich-Henn J, Mackensen F. Tocilizumab for anterior uveitis and juvenile idiopathic arthritis—a case report. Acta Ophthalmol. 2012;90. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2012.2277.x/abstract
   Google Scholar
• Adán A, Mesquida M, Llorenç V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632
   PubMed Web of Science ®Google Scholar
• Adán A, Mesquida M, Llorenç V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol 2014;252:163–164
   PubMed Web of Science ®Google Scholar
• Mesquida M, Leszczynska A, Llorenç V, Adán A. Interleukin-6 blockade in ocular inflammatory diseases. Clin Exp Immunol. 2014 Feb 15. doi: 10.1111/cei.12295. [Epub ahead of print]
   Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014; Dec 17. pii: S0161-6420(13)00893-2. doi: 10.1016/j.ophtha.2013.09.048. [Epub ahead of print]
   Google Scholar
• Mesquida M, Molins B, Llorenç V, et al. Current and future treatments for Behçet's uveitis: road to remission. Int Ophthalmol 2013 Jun 1. [Epub ahead of print]
   Google Scholar
• Lin P, Suhler EB, Rosenbaum JT. The future of uveitis treatment. Ophthalmology 2014;121:365–376
   PubMed Web of Science ®Google Scholar